Cargando…
Selective Use of Pulmonary Vasodilators in Patients with Fontan Physiology
BACKGROUND: Fontan-associated liver disease is a well-known sequela following the Fontan procedure for patients living with single-ventricle heart disease. Pulmonary vasodilators, such as phosphodiesterase type 5 inhibitors, have emerged as a potential therapeutic option for lowering central venous...
Autores principales: | Glenn, Thomas, Duster, Nicole, Dwek, Jerry, Silva-Sepulveda, Jose, El-Said, Howaida G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671729/ https://www.ncbi.nlm.nih.gov/pubmed/36447937 http://dx.doi.org/10.1155/2022/7602793 |
Ejemplares similares
-
Use of pulmonary vasodilators in Fontan patients: a useful strategy
to improve functional status and delay transplantation?
por: Lammers, Astrid E., et al.
Publicado: (2018) -
Pulmonary vasodilator therapy as treatment for patients with a Fontan circulation: the Emperor’s new clothes?
por: Ridderbos, Floris-Jan S., et al.
Publicado: (2018) -
The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials
por: Wang, Wuwan, et al.
Publicado: (2019) -
Exercise MRI highlights heterogeneity in cardiovascular mechanics among patients with Fontan circulation: proposed protocol for routine evaluation
por: Contijoch, Francisco, et al.
Publicado: (2020) -
Pulmonary vasodilator therapy for patients after Fontan procedure: A protocol for a systematic review and meta-analysis
por: Li, Dongxu, et al.
Publicado: (2019)